{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:51:13Z","timestamp":1794887473714,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the rapid development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in recent decades, resistance remains a significant challenge in managing advanced non-small cell lung cancer (NSCLC). Elucidating the mechanisms underlying EGFR-TKI resistance and developing novel strategies are therefore crucial. In this study, we investigated the role of polo-like kinase 1 (PLK1) in EGFR-mutant NSCLC and evaluated the therapeutic potential of combining EGFR-TKIs with PLK1 inhibitors. We demonstrated that high PLK1 expression correlates with STAT3 signaling activation and decreased survival probability in EGFR-mutant NSCLC patients. Subsequent studies revealed that PLK1 inhibitors effectively reversed the activation of STAT3 induced by EGFR-TKIs. When used in combination with EGFR-TKIs, they promoted cell apoptosis, inhibited cell proliferation in vitro, and induced tumor regression in animal models. Mechanistically, our data demonstrated that PLK1 regulated STAT3 activity through protein-protein interactions and JAK1-mediated phosphorylation, while STAT3 reciprocally regulated PLK1 transcription, establishing a positive feedback loop between these signaling molecules. This PLK1\/STAT3 loop was further reinforced by FGFR1 upregulation and directly linked to EGFR-TKI resistance. Targeting this axis with combinatorial inhibitors exerted synergistic anti-tumor effects, suppressing proliferation and migration in osimertinib-resistant models. In conclusion, concurrent inhibition of EGFR and FGFR1\/STAT3\/PLK1 signaling pathways provides a promising therapeutic strategy for NSCLC patients with EGFR mutations, enhancing efficacy and overcoming resistance.<\/jats:p>","DOI":"10.1038\/s41419-025-08220-9","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:44:19Z","timestamp":1768473859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1\/STAT3 pathway"],"prefix":"10.1038","volume":"17","author":[{"given":"Cheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangxuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-6256","authenticated-orcid":false,"given":"Yafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3572-5269","authenticated-orcid":false,"given":"Chengying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"8220_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Prim. 2024;10:71.","journal-title":"Nat Rev Dis Prim"},{"key":"8220_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, et al. Management of locally advanced non-small cell lung cancer: state of the art and future directions. Cancer Commun. 2024;44:23\u201346.","journal-title":"Cancer Commun"},{"key":"8220_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356.","journal-title":"Nat Med"},{"key":"8220_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375.","journal-title":"Semin Cancer Biol"},{"key":"8220_CR5","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","volume":"11","author":"CB Meador","year":"2021","unstructured":"Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11:2145\u201357.","journal-title":"Cancer Discov"},{"key":"8220_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878:188967.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8220_CR7","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","volume":"29","author":"SM Lim","year":"2023","unstructured":"Lim SM, Fujino T, Lee GH, Kim C, Lee YH, Kim DW, et al. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant egfr mutations in non-small cell lung cancer. Clin Cancer Res. 2023;29:3004\u201316.","journal-title":"Clin Cancer Res"},{"key":"8220_CR8","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","volume":"65","author":"MS Eno","year":"2022","unstructured":"Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, et al. Discovery of BLU-945, a Reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. J Med Chem. 2022;65:9662\u201377.","journal-title":"J Med Chem"},{"key":"8220_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","volume":"385","author":"SH Wang","year":"2017","unstructured":"Wang SH, Song YP, Liu DL. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51\u201354.","journal-title":"Cancer Lett"},{"key":"8220_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.","journal-title":"J Hematol Oncol"},{"key":"8220_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, et al. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"key":"8220_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"LH Huang","year":"2015","unstructured":"Huang LH, Fu LW. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401.","journal-title":"Acta Pharm Sin B"},{"key":"8220_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189207","volume":"1879","author":"D Shi","year":"2024","unstructured":"Shi D, Tao J, Man S, Zhang N, Ma L, Guo L, et al. Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy. Biochim Biophys Acta Rev Cancer. 2024;1879:189207.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8220_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216612","volume":"586","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhou QQ, Liu C, Zhang RZ, Xing BF, Du J, et al. Targeting IL-6\/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC. Cancer Lett. 2024;586:216612.","journal-title":"Cancer Lett"},{"key":"8220_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang GL, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207\u201321.","journal-title":"Cancer Cell"},{"key":"8220_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188645","volume":"1877","author":"X Tian","year":"2022","unstructured":"Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188645.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8220_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1158\/0008-5472.CAN-20-1377","volume":"81","author":"L Gheghiani","year":"2021","unstructured":"Gheghiani L, Wang L, Zhang YW, Moore XTR, Zhang JL, Smith SC, et al. PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis. Cancer Res. 2021;81:1293\u2013307.","journal-title":"Cancer Res"},{"key":"8220_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06506-6","volume":"621","author":"C Gelot","year":"2023","unstructured":"Gelot C, Kovacs MT, Miron S, Mylne E, Haan A, Boeffard-Dosierre L, et al. Pol\u03b8 is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Nature. 2023;621:415\u201322.","journal-title":"Nature"},{"key":"8220_CR19","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1080\/15548627.2020.1851492","volume":"17","author":"PH Luo","year":"2021","unstructured":"Luo PH, Yan H, Du JX, Chen XQ, Shao JJ, Zhang Y, et al. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy. 2021;17:3221\u201337.","journal-title":"Autophagy"},{"key":"8220_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41388-021-02077-w","volume":"41","author":"C Yu","year":"2022","unstructured":"Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, et al. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene. 2022;41:191\u2013203.","journal-title":"Oncogene"},{"key":"8220_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tranon.2016.10.003","volume":"10","author":"ZX Liu","year":"2017","unstructured":"Liu ZX, Sun QR, Wang XS. PLK1, a potential target for cancer therapy. Transl Oncol. 2017;10:22\u201332.","journal-title":"Transl Oncol"},{"key":"8220_CR22","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.7150\/thno.61711","volume":"11","author":"A Hagege","year":"2021","unstructured":"Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, et al. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy. Theranostics. 2021;11:9571\u201386.","journal-title":"Theranostics"},{"key":"8220_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/neuonc\/noab207","volume":"24","author":"D Wang","year":"2022","unstructured":"Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, et al. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-Oncol. 2022;24:414\u201326.","journal-title":"Neuro-Oncol"},{"key":"8220_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.7150\/thno.79318","volume":"13","author":"D Kim","year":"2023","unstructured":"Kim D, Shin SB, Kim CH, Kim YB, Oh HJ, Yim H. PLK1-mediated phosphorylation of \u03b2-catenin enhances its stability and transcriptional activity for extracellular matrix remodeling in metastatic NSCLC. Theranostics. 2023;13:1198\u2013216.","journal-title":"Theranostics"},{"key":"8220_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31926-9","volume":"13","author":"M Reda","year":"2022","unstructured":"Reda M, Ngamcherdtrakul W, Nelson MA, Siriwon N, Wang RJ, Zaidan HY, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13:4261.","journal-title":"Nat Commun"},{"key":"8220_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41388-019-1023-z","volume":"39","author":"SB Shin","year":"2020","unstructured":"Shin SB, Jang HR, Xu R, Won JY, Yim H. Active PLK1-driven metastasis is amplified by TGF-\u03b2 signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene. 2020;39:767\u201385.","journal-title":"Oncogene"},{"key":"8220_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson MB, Sun HY, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12:eaaz4589.","journal-title":"Sci Transl Med"},{"key":"8220_CR28","doi-asserted-by":"publisher","first-page":"28731","DOI":"10.1200\/JCO.2017.35.15_suppl.e14104","volume":"35","author":"A Noor","year":"2017","unstructured":"Noor A, Umelo IA, Kronenberger P, Teugels E, De Greve J. Targeting polo-like kinase 1 and TRAIL to enhance apoptosis in non-small cell lung cancer (NSCLC) cells. J Clin Oncol. 2017;35:28731\u201344.","journal-title":"J Clin Oncol"},{"key":"8220_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114747","volume":"193","author":"S Iliaki","year":"2021","unstructured":"Iliaki S, Beyaert R, Afonina IS. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharm. 2021;193:114747.","journal-title":"Biochem Pharm"},{"key":"8220_CR30","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1538-7445.AM2017-4178","volume":"77","author":"S Moureau","year":"2017","unstructured":"Moureau S, MacKay C, Saladino C, Pohler E, Kroboth K, Hollick J, et al. The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Cancer Res. 2017;77:4178.","journal-title":"Cancer Res"},{"key":"8220_CR31","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/JTO.0b013e3181d95dd4","volume":"5","author":"M Sebastian","year":"2010","unstructured":"Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB\/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy. J Thorac Oncol. 2010;5:1060\u20137.","journal-title":"J Thorac Oncol"},{"key":"8220_CR32","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-12-0006-T","volume":"11","author":"C McInnes","year":"2012","unstructured":"McInnes C, Estes K, Baxter M, Yang ZG, Farag DB, Johnston P, et al. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012;11:1683\u201392.","journal-title":"Mol Cancer Ther"},{"key":"8220_CR33","doi-asserted-by":"publisher","first-page":"S1019","DOI":"10.1016\/j.annonc.2022.07.1144","volume":"33","author":"R Veluswamy","year":"2022","unstructured":"Veluswamy R, Bhalla S, Samstein R, Marron T, Gomez JE, Doroshow DB, et al. Phase I\/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients. Ann Oncol. 2022;33:S1019\u2013S1020.","journal-title":"Ann Oncol"},{"key":"8220_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101332","volume":"16","author":"SQ Su","year":"2022","unstructured":"Su SQ, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Transl Oncol. 2022;16:101332.","journal-title":"Transl Oncol"},{"key":"8220_CR35","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-23-3053","volume":"30","author":"DH Ahn","year":"2024","unstructured":"Ahn DH, Barzi A, Ridinger M, Samu\u00eblsz E, Subramanian RA, Croucher PJP, et al. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clin Cancer Res. 2024;30:2039\u201347.","journal-title":"Clin Cancer Res"},{"key":"8220_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179\u201386.","journal-title":"Cancer Sci"},{"key":"8220_CR37","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/cancers15092589","volume":"15","author":"C Eggermont","year":"2023","unstructured":"Eggermont C, Gutierrez GJ, De Gr\u00e8ve J, Giron P. Inhibition of PLK1 destabilizes EGFR and sensitizes EGFR-mutated lung cancer cells to small molecule inhibitor osimertinib. Cancers. 2023;15:2589.","journal-title":"Cancers"},{"key":"8220_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejmech.2019.04.024","volume":"174","author":"GP Cai","year":"2019","unstructured":"Cai GP, Yu WY, Song DM, Zhang WD, Guo JP, Zhu JW, et al. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors. Eur J Med Chem. 2019;174:236\u201351.","journal-title":"Eur J Med Chem"},{"key":"8220_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","volume":"10","author":"LX Song","year":"2011","unstructured":"Song LX, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011;10:481\u201394.","journal-title":"Mol Cancer Ther"},{"key":"8220_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2011.11.023","volume":"142","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, et al. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology. 2012;142:521\u2013530.e523.","journal-title":"Gastroenterology"},{"key":"8220_CR41","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-20-1192","volume":"80","author":"YH Lu","year":"2020","unstructured":"Lu YH, Liu YF, Oeck S, Zhang GJ, Schramm A, Glazer PM. Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway. Cancer Res. 2020;80:4655\u201367.","journal-title":"Cancer Res"},{"key":"8220_CR42","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3389\/fphar.2019.01533","volume":"10","author":"GZ Chen","year":"2020","unstructured":"Chen GZ, Bao YY, Weng QY, Zhao YX, Lu XY, Fu LL, et al. Compound 15c, a novel dual inhibitor of EGFR L858R\/T790M and FGFR1, efficiently overcomes epidermal growth factor receptor-tyrosine kinase inhibitor resistance of non-small-cell lung cancers. Front Pharm. 2020;10:1533.","journal-title":"Front Pharm"},{"key":"8220_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10637-017-0491-7","volume":"36","author":"GJ Weiss","year":"2018","unstructured":"Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, et al. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Investigl N Drugs. 2018;36:85\u201395.","journal-title":"Investigl N Drugs"},{"key":"8220_CR44","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","volume":"39","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Yu HA, Yang SY, Han S, Selcuklu SD, Kim K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021;39:1245\u201361.","journal-title":"Cancer Cell"},{"key":"8220_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23053-8","volume":"12","author":"WG Shi","year":"2021","unstructured":"Shi WG, Zhang GY, Ma ZJ, Li LS, Liu MM, Qin L, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021;12:2812.","journal-title":"Nat Commun"},{"key":"8220_CR46","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41418-021-00781-4","volume":"28","author":"HR Jang","year":"2021","unstructured":"Jang HR, Shin SB, Kim CH, Won JY, Xu R, Kim DE, et al. PLK1\/vimentin signaling facilitates immune escape by recruiting Smad2\/3 to PD-L1 promoter in metastatic lung adenocarcinoma. Cell Death Differ. 2021;28:2745\u201364.","journal-title":"Cell Death Differ"},{"key":"8220_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-023-00466-3","volume":"12","author":"YF Wang","year":"2023","unstructured":"Wang YF, Yao MY, Li C, Yang KX, Qin XL, Xu LS, et al. Targeting ST8SIA6-AS1 counteracts KRAS G12C inhibitor resistance through abolishing the reciprocal activation of PLK1\/c-Myc signaling. Exp Hematol Oncol. 2023;12:105.","journal-title":"Exp Hematol Oncol"},{"key":"8220_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ijms22020603","volume":"22","author":"M Tolomeo","year":"2021","unstructured":"Tolomeo M, Cascio A. The multifaced Role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021;22:603.","journal-title":"Int J Mol Sci"},{"key":"8220_CR49","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","volume":"81","author":"L Zhu","year":"2021","unstructured":"Zhu L, Chen Z, Zang HJ, Fan SQ, Gu JJ, Zhang GJ, et al. Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib. Cancer Res. 2021;81:4822\u201334.","journal-title":"Cancer Res"},{"key":"8220_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"8220_CR51","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2021-151125","volume":"138","author":"PCC Liu","year":"2021","unstructured":"Liu PCC, Dixit V, Mayo M, Dey J, Yuan K, Karnik R, et al. A first-in-Class STAT3 degrader KT-333 in development for treatment of hematologic cancers. Blood. 2021;138:1865.","journal-title":"Blood"},{"key":"8220_CR52","doi-asserted-by":"publisher","first-page":"181130","DOI":"10.1182\/blood-2023-181130","volume":"142","author":"A Shastri","year":"2023","unstructured":"Shastri A, Feldman EJ, Starodub AN, Feldman T, Rodriguez CP, Epstein-Peterson ZD, et al. Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors. Blood. 2023;142:181130.","journal-title":"Blood"},{"key":"8220_CR53","doi-asserted-by":"crossref","unstructured":"Waliany S, Lin JJ, Gainor JF. Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends Cancer 2025;11:p245\u20137.","DOI":"10.1016\/j.trecan.2025.01.005"},{"key":"8220_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"8220_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00208-w","volume":"5","author":"MG Terp","year":"2021","unstructured":"Terp MG, Jacobsen K, Molina MA, Karachaliou N, Beck HC, Bertran-Alamillo J, et al. Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. npj Precis Oncol. 2021;5:65.","journal-title":"npj Precis Oncol"},{"key":"8220_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16952-9","volume":"11","author":"JMF Neto","year":"2020","unstructured":"Neto JMF, Nadal E, Bosdriesz E, Ooft SN, Farre L, McLean C, et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nat Commun. 2020;11:3157.","journal-title":"Nat Commun"},{"key":"8220_CR57","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang TH, Fan MY, Vajdi A, et al. Treatment-induced tumor dormancy through yap-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37:104\u201322.","journal-title":"Cancer Cell"},{"key":"8220_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217124","volume":"598","author":"R Nakamura","year":"2024","unstructured":"Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Lett. 2024;598:217124.","journal-title":"Cancer Lett"},{"key":"8220_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34889-z","volume":"13","author":"SJ Adua","year":"2022","unstructured":"Adua SJ, Arnal-Estap\u00e9 A, Zhao M, Qi B, Liu ZZZ, Kravitz C, et al. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer. Nat Commun. 2022;13:7690.","journal-title":"Nat Commun"},{"key":"8220_CR60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13402-017-0345-5","volume":"40","author":"M Yousefi","year":"2017","unstructured":"Yousefi M, Bahrami T, Salmaninejad A, Nosrati R, Ghaffari P, Ghaffari SH. Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol. 2017;40:419\u201341.","journal-title":"Cell Oncol"},{"key":"8220_CR61","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290.","journal-title":"J Clin Oncol"},{"key":"8220_CR62","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702.","journal-title":"J Clin Oncol"},{"key":"8220_CR63","doi-asserted-by":"publisher","first-page":"e77053","DOI":"10.1371\/journal.pone.0077053","volume":"8","author":"D Danovi","year":"2013","unstructured":"Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh AMO, Engstr\u00f6m PG, et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. Plos ONE. 2013;8:e77053.","journal-title":"Plos ONE"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08220-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08220-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:03:33Z","timestamp":1768478613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08220-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8220"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08220-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All in vivo experiments were performed according to the Institutional Ethical Guidelines on Animal Care and were approved by the Institute of Animal Care and Use Committee at the Lingang Laboratory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval And Consent To Participate"}}],"article-number":"41"}}